24.1 USD
-0.3 (-1.23%)
24.1 USD
0 (0%)
SMTI gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 187 industry peers in the Health Care Equipment & Supplies industry. SMTI may be in some trouble as it scores bad on both profitability and health. SMTI is not valued too expensively and it also shows a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year SMTI has reported negative net income.
SMTI had a positive operating cash flow in the past year.
In the past 5 years SMTI always reported negative net income.
SMTI had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
SMTI has a worse Return On Assets (-52.74%) than 67.91% of its industry peers.
With a Return On Equity value of -609.72%, SMTI is not doing good in the industry: 82.89% of the companies in the same industry are doing better.
The Return On Invested Capital of SMTI (2.18%) is better than 68.98% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -52.74% | ||
| ROE | -609.72% | ||
| ROIC | 2.18% |
ROA(3y)-9.93%
ROA(5y)-19.18%
ROE(3y)-17.7%
ROE(5y)-29.97%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
Looking at the Operating Margin, with a value of 1.46%, SMTI is in the better half of the industry, outperforming 66.31% of the companies in the same industry.
The Gross Margin of SMTI (92.25%) is better than 97.86% of its industry peers.
SMTI's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 1.46% | ||
| PM (TTM) | N/A | ||
| GM | 92.25% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.07%
GM growth 5Y0.2%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), SMTI is destroying value.
SMTI has more shares outstanding than it did 1 year ago.
SMTI has more shares outstanding than it did 5 years ago.
SMTI has a worse debt/assets ratio than last year.
2.2 Solvency
SMTI has an Altman-Z score of 2.28. This is not the best score and indicates that SMTI is in the grey zone with still only limited risk for bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 2.28, SMTI is in the better half of the industry, outperforming 64.17% of the companies in the same industry.
A Debt/Equity ratio of 7.33 is on the high side and indicates that SMTI has dependencies on debt financing.
With a Debt to Equity ratio value of 7.33, SMTI is not doing good in the industry: 86.10% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 7.33 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 2.28 |
ROIC/WACC0.26
WACC8.55%
2.3 Liquidity
A Current Ratio of 1.80 indicates that SMTI should not have too much problems paying its short term obligations.
The Current ratio of SMTI (1.80) is worse than 67.38% of its industry peers.
A Quick Ratio of 1.60 indicates that SMTI should not have too much problems paying its short term obligations.
With a Quick ratio value of 1.60, SMTI perfoms like the industry average, outperforming 42.25% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.8 | ||
| Quick Ratio | 1.6 |
3. Growth
3.1 Past
SMTI shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 26.06%, which is quite impressive.
The Revenue has grown by 30.55% in the past year. This is a very strong growth!
Measured over the past years, SMTI shows a very strong growth in Revenue. The Revenue has been growing by 49.08% on average per year.
EPS 1Y (TTM)26.06%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%126.47%
Revenue 1Y (TTM)30.55%
Revenue growth 3Y53.13%
Revenue growth 5Y49.08%
Sales Q2Q%21.51%
3.2 Future
The Earnings Per Share is expected to grow by 60.78% on average over the next years. This is a very strong growth
SMTI is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 15.94% yearly.
EPS Next Y117%
EPS Next 2Y76.21%
EPS Next 3Y60.78%
EPS Next 5YN/A
Revenue Next Year19.89%
Revenue Next 2Y18.28%
Revenue Next 3Y15.94%
Revenue Next 5YN/A
3.3 Evolution
The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
4. Valuation
4.1 Price/Earnings Ratio
SMTI reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
The Price/Forward Earnings ratio is 19.13, which indicates a rather expensive current valuation of SMTI.
SMTI's Price/Forward Earnings ratio is rather cheap when compared to the industry. SMTI is cheaper than 82.35% of the companies in the same industry.
SMTI is valuated rather cheaply when we compare the Price/Forward Earnings ratio to 23.96, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 19.13 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, SMTI is valued a bit cheaper than 68.98% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | 38.53 |
4.3 Compensation for Growth
SMTI's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
SMTI's earnings are expected to grow with 60.78% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y76.21%
EPS Next 3Y60.78%
5. Dividend
5.1 Amount
SMTI does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
24.1
-0.3 (-1.23%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners12.93%
Inst Owner Change1.65%
Ins Owners8.75%
Ins Owner Change-0.04%
Market Cap215.45M
Revenue(TTM)101.90M
Net Income(TTM)-37.49M
Analysts82.5
Price Target41.82 (73.53%)
Short Float %7.19%
Short Ratio5.54
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)94.9%
Min EPS beat(2)48.75%
Max EPS beat(2)141.04%
EPS beat(4)3
Avg EPS beat(4)39.09%
Min EPS beat(4)-53.45%
Max EPS beat(4)141.04%
EPS beat(8)5
Avg EPS beat(8)-0.7%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)-1.17%
Min Revenue beat(2)-3.03%
Max Revenue beat(2)0.69%
Revenue beat(4)1
Avg Revenue beat(4)-1.13%
Min Revenue beat(4)-3.03%
Max Revenue beat(4)0.69%
Revenue beat(8)4
Avg Revenue beat(8)0.62%
Revenue beat(12)5
Avg Revenue beat(12)-2.06%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-18%
PT rev (3m)-18%
EPS NQ rev (1m)370.83%
EPS NQ rev (3m)370.83%
EPS NY rev (1m)119.39%
EPS NY rev (3m)119.39%
Revenue NQ rev (1m)-7.03%
Revenue NQ rev (3m)-7.03%
Revenue NY rev (1m)-2.33%
Revenue NY rev (3m)-2.33%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 19.13 | ||
| P/S | 2.11 | ||
| P/FCF | N/A | ||
| P/OCF | 57.03 | ||
| P/B | 35.04 | ||
| P/tB | N/A | ||
| EV/EBITDA | 38.53 |
EPS(TTM)-0.73
EYN/A
EPS(NY)1.26
Fwd EY5.23%
FCF(TTM)-0.1
FCFYN/A
OCF(TTM)0.42
OCFY1.75%
SpS11.4
BVpS0.69
TBVpS-2.08
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -52.74% | ||
| ROE | -609.72% | ||
| ROCE | 2.76% | ||
| ROIC | 2.18% | ||
| ROICexc | 3.02% | ||
| ROICexgc | 8.32% | ||
| OM | 1.46% | ||
| PM (TTM) | N/A | ||
| GM | 92.25% | ||
| FCFM | N/A |
ROA(3y)-9.93%
ROA(5y)-19.18%
ROE(3y)-17.7%
ROE(5y)-29.97%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.07%
GM growth 5Y0.2%
F-Score4
Asset Turnover1.43
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 7.33 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | 7.07 | ||
| Cap/Depr | 95.41% | ||
| Cap/Sales | 4.58% | ||
| Interest Coverage | 0.49 | ||
| Cash Conversion | 59.26% | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.8 | ||
| Quick Ratio | 1.6 | ||
| Altman-Z | 2.28 |
F-Score4
WACC8.55%
ROIC/WACC0.26
Cap/Depr(3y)14.51%
Cap/Depr(5y)146.81%
Cap/Sales(3y)0.77%
Cap/Sales(5y)3.19%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)26.06%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%126.47%
EPS Next Y117%
EPS Next 2Y76.21%
EPS Next 3Y60.78%
EPS Next 5YN/A
Revenue 1Y (TTM)30.55%
Revenue growth 3Y53.13%
Revenue growth 5Y49.08%
Sales Q2Q%21.51%
Revenue Next Year19.89%
Revenue Next 2Y18.28%
Revenue Next 3Y15.94%
Revenue Next 5YN/A
EBIT growth 1Y131.13%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y73.16%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y224.27%
OCF growth 3YN/A
OCF growth 5YN/A
SANARA MEDTECH INC / SMTI FAQ
What is the ChartMill fundamental rating of SANARA MEDTECH INC (SMTI) stock?
ChartMill assigns a fundamental rating of 3 / 10 to SMTI.
What is the valuation status for SMTI stock?
ChartMill assigns a valuation rating of 4 / 10 to SANARA MEDTECH INC (SMTI). This can be considered as Fairly Valued.
How profitable is SANARA MEDTECH INC (SMTI) stock?
SANARA MEDTECH INC (SMTI) has a profitability rating of 2 / 10.
How financially healthy is SANARA MEDTECH INC?
The financial health rating of SANARA MEDTECH INC (SMTI) is 2 / 10.
What is the expected EPS growth for SANARA MEDTECH INC (SMTI) stock?
The Earnings per Share (EPS) of SANARA MEDTECH INC (SMTI) is expected to grow by 117% in the next year.